Artivion, Inc. (NYSE:AORT) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in Artivion, Inc. (NYSE:AORT) by 0.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,804,884 shares of the company’s stock after acquiring an additional 1,771 shares during the quarter. Vanguard Group Inc. owned 6.69% of Artivion worth $80,192,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its stake in shares of Artivion by 28.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock worth $522,000 after acquiring an additional 4,295 shares in the last quarter. FMR LLC boosted its position in Artivion by 28.0% during the third quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after purchasing an additional 25,176 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Artivion by 543.0% in the third quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock valued at $761,000 after purchasing an additional 24,130 shares during the last quarter. Quarry LP grew its holdings in Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Artivion by 2.9% in the third quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after buying an additional 46,267 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Stifel Nicolaus lowered their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Needham & Company LLC lowered their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.40.

Insider Buying and Selling

In other Artivion news, CEO James P. Mackin sold 42,156 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the transaction, the chief executive officer now owns 663,882 shares of the company’s stock, valued at $18,130,617.42. This represents a 5.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 18,020 shares of Artivion stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the sale, the senior vice president now directly owns 197,184 shares of the company’s stock, valued at approximately $4,655,514.24. This represents a 8.37 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is owned by insiders.

Artivion Stock Down 1.8 %

AORT opened at $23.53 on Friday. The firm has a market cap of $989.35 million, a P/E ratio of -1,176.45 and a beta of 1.65. The business’s fifty day simple moving average is $25.98 and its 200 day simple moving average is $27.50. Artivion, Inc. has a 52 week low of $19.36 and a 52 week high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.